GC Biopharma Corp.

Total Valuation

GC Biopharma Corp. carries a market capitalization of 1.43T, placing it among publicly traded companies globally. Its enterprise value stands at 2.58T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

GC Biopharma Corp. currently has 11.41M shares outstanding.

Valuation Ratios

GC Biopharma Corp. trades at a trailing price-to-earnings ratio of 34.31. The price-to-sales ratio is 0.80, and the price-to-book ratio stands at 1.90.

Enterprise Valuation

On an enterprise value basis, GC Biopharma Corp. trades at an EV/EBITDA multiple of 35.42 and an EV/FCF ratio of 7.16. The EV/Sales ratio of 1.26 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 35.42 provides insight into valuation relative to core operating earnings.

Financial Position

GC Biopharma Corp. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 69.85, indicating elevated leverage, while an interest coverage ratio of 1.40 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, GC Biopharma Corp. has paid 8.37B in income taxes, reflecting an effective tax rate of 58.00.

Stock Price Statistics

GC Biopharma Corp.'s stock has declined approximately -3.99386% over the past 52 weeks. The 50-day moving average sits at 132,074.00, while the 200-day moving average is 144,013.50.

Income Statement

Over the trailing twelve months, GC Biopharma Corp. generated 2.04T in revenue and converted that into -13.90B in net income, yielding earnings per share of -2,787.98. EBITDA reached 72.92B, while operating income came in at 72.92B.

Balance Sheet

GC Biopharma Corp. holds 42.73B in cash and equivalents against 914.33B in total debt, resulting in a net debt position of 765.58B. Total book value stands at 858.32B, with working capital of 258.41B providing operational flexibility.

Cash Flow

GC Biopharma Corp. produced 161.14B in operating cash flow over the past twelve months. After subtracting -129.21B in capital expenditures, free cash flow totaled 31.93B - equivalent to 2,797.89 per share.

Margins

GC Biopharma Corp. operates with a gross margin of 27.61, reflecting its pricing power and cost economics. The operating margin of 3.57 and net profit margin of -0.68 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -0.05 indicates the proportion of earnings distributed to shareholders.

Stock Splits

GC Biopharma Corp.'s most recent stock split took place on June 7, 2013 with a 20:21 split ratio.

Scores

GC Biopharma Corp. posts an Altman Z-Score of 2.19, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.